Benzinga's Top #PreMarket Losers

Salix Pharmaceuticals SLXP shares slipped 33.79% to $91.74 in pre-market trading after the company reported downbeat Q3 results and appointed Timothy Creech as CFO. Analysts at Stifel Nicolaus downgraded Salix Pharma from Buy to Hold and removed the price target of $189. Performant Financial PFMT fell 18.96% to $7.01 in pre-market trading after the company reported downbeat Q3 results and lowered its FY14 revenue forecast. William Blair downgraded Performant Financial from Outperform to Market Perform. Intercept Pharmaceuticals ICPT shares declined 14.97% to $210.00 in pre-market trading after the company reported a Q3 loss of $1.69 per share and announced that results from the FLINT trial in nonalcoholic steatohepatitis (NASH) were published in The Lancet. Ubiquiti Networks UBNT shares dropped 14.79% to $29.50 in pre-market trading after the company reported weaker-than-expected FQ1 results and issued a downbeat Q2 outlook. Wunderlich lowered the price target on Ubiquiti Networks from $55.00 to $50.00.